Takeda Pharmaceutical Company Limited

Headquarters: Tokyo, Japan

Founded: Doshomachi, Osaka, Japan June 12, 1781

Employees: 47,099

CEO: Mr. Christophe Weber

JPX: 4502 +0.10%

Market Cap

¥6.720 Trillion

JPY as of Jan. 1, 2024

US$47.71 Billion

Market Cap History

Takeda Pharmaceutical Company Limited market capitalization over time

Evolution of Takeda Pharmaceutical Company Limited market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Takeda Pharmaceutical Company Limited

Detailed Description

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro, and Alunbrig brands. Takeda Pharmaceutical Company has licensing agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; license and research agreements with The University of Texas MD Anderson Cancer Center, Poseida Therapeutics, Inc., and Arrowhead Pharmaceuticals Inc.; research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; HemoShear Therapeutics, LLC; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Top 1-year algo backtest: +181.22%

$10,000 in June 2023 would now be $28,122 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Takeda Pharmaceutical Company Limited has the following listings and related stock indices.

Stock: JPX: 4502 wb_incandescent

Stock: FSX: TKD wb_incandescent

Stock: OTC: TKPHF wb_incandescent

Stock: NYSE: TAK wb_incandescent

Stock: BMV: TAKN wb_incandescent

Stock: XSTU: TKDA wb_incandescent

Stock: FSX: TKDA wb_incandescent

Key People

Founder(s): Chobei Takeda I

Yasuchika Hasegawa (Chairman of the Board) Christophe Weber (President & CEO)


Revenue: ¥1,770,531 million (FY 2018)[* 1]

Operating income: ¥241,789 million (FY 2018)[* 1]

Net income: ¥186,886 million (FY 2012)[* 1]

Total assets: ¥4,106,463 billion (FY 2018)[* 1]

Total equity: ¥1,997,424 billion (FY 2018)[* 1]



1-1, Nihonbashi-Honcho 2-chome


Tokyo, 103-8668


Phone: 81 3 3278 2306

Fax: 81 3 3278 2268